<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211023052845N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-12-20</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effect of vancomycin and betadine on wound infection</public_title>
      <acronym></acronym>
      <scientific_title>The Effect of of Vancomycin powder and Povidon-Iodine in the Prevention of Wound infection in Open Lower-limb Fractures Undergoing Open Reduction and Internal Fixation</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/59556</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Randomization method: Simple randomization
The method of assigning people to two groups of control and intervention will be so that the researcher uses a random table of numbers. This table contains a set of masses of numbers that are produced without a specific pattern or order and completely randomly and It is shown as a table. The researcher will consider two columns A (intervention) and B (control). After that the researcher touches one of the table numbers randomly and without looking at the table. If the even number is placed under the finger, the even sample will be considered for column A (intervention group) and if the odd number is placed, will be considered for column B (control group). Until it reaches the desired sample size in each group, Blinding description: completely, the purpose of the study will be explained to patients, and if they are satisfied, those who have criteria for entering and answer positively to the research proposal will enter the study. All patients will be explained how to intervene, but patients will have no information about whether they will be allocated in the control or intervention group, and after sampling and analyzing the data, Information is given for both groups to performance of ethic of research (single blind). 
The intervention is performed by the researcher but randomization of people is done by the researcher, expert colleague to determine the control group or intervention and the researcher is unaware of the process until the end of the sampling stage. Before the researcher enters the operation field, the solution, will be provided by the research colleague. It should be noted that Poidon Aidan solution alone, have the same color and odor as well as the combination of betadine and vancomycin, , and experiments have confirmed this (double-blind). 
The statistical analyzer and the data safety and monitoring committee have no information about which data belongs to which control or intervention group, and only the checklist that filled by the researcher during the evaluation and analysis of the data is provided to them (triple-blind).</study_design>
      <phase>N/A</phase>
      <hc_freetext>Open Fractures in Limbs.</hc_freetext>
      <i_freetext>Intervention 1: In the intervention group, after primary skin prep with betadine 7%, for secondary prep, 10% betadine solution with vancomycin powder in the amount of 2 g is used and it will be done using 3 sterile sponge. Intervention 2: Control group: Control group: In the control group, after primary skin prep with betadine 7%, for secondary prep, betadine 10% alone (routine method) is used using 3 sterile gases.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Published with the necessary coordination</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Yaser Abolhasani Heydarabad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.24, Shahidan Abdolahi, Shahid Hoseini Blvd</address>
        <city>Rafsanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7719678396</zip>
        <telephone>+98 34 3422 5147</telephone>
        <email>yaserabolhasani@yahoo.co.uk</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Soheila Bakhtiari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hezar jarib</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174673461</zip>
        <telephone>+98 31 3792 7510</telephone>
        <email>bakhtiari@nm.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Diagnosis of open fracture and the need for open reduction and internal fixation surgery
The patient should not be referred to the operating room as a vital emergency and should be fasted for 8 hours before the operation
Age between 18 and 65 years
Having a body mass index between 18 and 25
Not pregnant during the study
Lack of sensitivity to seafood
No autoimmune diseases and immune system defects (Guillain-Barre, multiple sclerosis, immune deficiency syndrome, etc.)
Not having any declining bone disease
Do not take antibiotics one week before surgery
No skin diseases
No history of orthopedic and neurosurgery during the last 6 months
Absence of cIII degree open fractures in Gastillo Anderson classification
No smoking and drug addiction
Lack of underlying and autoimmune diseases (diabetes, multiple sclerosis, immune deficiency syndrome, etc.)
No previous allergy to antibiotics and disinfectants
Informed consent</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Intraoperative blood transfusion
Unforeseen events before surgery such as cardiac arrest and death
Patient death during study (within 30 days after surgery)
Bleeding more than 200 cc
Duration of surgery more than 2 hours
Arbitrary use of antibiotics without a doctor's prescription
The interval between going to the emergency room and surgery is more than 23 hours
Reluctance to continue participating in research</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T14.8</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Injury of unspecified body region</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In the intervention group, after primary skin prep with betadine 7%, for secondary prep, 10% betadine solution with vancomycin powder in the amount of 2 g is used and it will be done using 3 sterile sponge.</i_keyword>
      <i_keyword>Control group: Control group: In the control group, after primary skin prep with betadine 7%, for secondary prep, betadine 10% alone (routine method) is used using 3 sterile gases.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Infection. Timepoint: The first, second, fourteenth and twenty-eighth days after surgery. Method of measurement: Visual scale analog and laboratory sampling.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-10-20</approval_date>
        <contact_name>کمیته اخلاق دانشگاه علوم پزشکی اصفهان</contact_name>
        <contact_address>Hezar Jarib Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
